Comparative Pharmacology
Head-to-head clinical analysis: DUO MEDIHALER versus OXYBUTYNIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUO MEDIHALER versus OXYBUTYNIN.
DUO-MEDIHALER vs OXYBUTYNIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone propionate, a corticosteroid with anti-inflammatory activity, and salmeterol, a long-acting beta2-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating intracellular adenyl cyclase, increasing cyclic AMP levels.
Oxybutynin is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the bladder detrusor muscle, inhibiting involuntary contractions and increasing bladder capacity.
Two inhalations (50 mcg ipratropium bromide and 100 mcg fenoterol hydrobromide per inhalation) four times daily via metered-dose inhaler.
5 mg orally 2-3 times daily; maximum 5 mg 4 times daily. Extended-release: 5-10 mg orally once daily; maximum 30 mg/day. Transdermal: 3.9 mg/day patch applied every 3-4 days. Topical gel: 1 g (3 pumps) applied once daily.
None Documented
None Documented
Clinical Note
moderateOxybutynin + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Oxybutynin."
Clinical Note
moderateOxybutynin + Fluconazole
Terminal elimination half-life of 3-4 hours for the bronchodilator component and 6-8 hours for the corticosteroid component; clinically requires twice-daily dosing.
Terminal half-life: 12-13 hours (range 7-20 hours) in healthy adults. In elderly, half-life may be prolonged due to reduced clearance.
Renal: 70-80% (free drug and metabolites), Biliary/Fecal: 10-20%
Primarily hepatic metabolism; less than 1% excreted unchanged in urine. Metabolites are mainly excreted renally (50%) and fecally (40%).
Category C
Category A/B
Anticholinergic/Beta2-Agonist Combination
Anticholinergic
"The metabolism of Fluconazole can be decreased when combined with Oxybutynin."